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Abstract The premature cancer mortality rate has been
declining in Switzerland, but there has been considerable
variation in the rate of decline across cancer sites (e.g., breast
or digestive organs). I analyze the effect that pharmaceutical
innovation had on premature cancer mortality in Switzerland
during the period 1995–2012 by investigating whether the
cancer sites that experienced more pharmaceutical innova-
tion had larger declines in premature mortality, controlling
for the number of people diagnosed and mean age at diag-
nosis. Premature cancer mortality before ages 75 and 65 is
significantly inversely related to the cumulative number of
drugs registered 5, 10, and 15 years earlier. The number of
drugs registered during 1980–1997 explains 63 % of the
variation across cancer sites in the 1995–2012 log change in
the premature (before age 75) mortality rate. Controlling for
the cumulative number of drugs, the cumulative number of
chemical subgroups does not have a statistically significant
effect on premature mortality. This suggests that drugs
(chemical substances) within the same class (chemical sub-
group) are not ‘‘therapeutically equivalent’’. Over 17,000
life-years before age 75 were gained in 2012 due to drugs
registered during 1990–2007. The number of life-years
before age 75 gained in 2012 from drugs registered during
two earlier periods (1985–2002 and 1980–1997) were more
than twice as great. Since mean utilization of new drugs is
much lower than mean utilization of older drugs, more recent
drug registrations may have a smaller effect on premature
mortality than earlier drug registrations even if the average
quality of newer drugs is higher. Estimates of the cost per
life-year gained before ages 75 and 65 in 2012 from drugs
registered during 1990–2007 are $21,228 and $28,673,
respectively. These figures are below even the lowest esti-
mates from the value-of-life literature of the value of a
quality-adjusted life-year. The estimates indicate that the cost
per life-year before age 75 gained from drugs registered
during earlier periods (1985–2002 and 1980–1997) were
considerably lower: $5299 and $3218, respectively. The
largest reductions in premature mortality occur at least a
decade after drugs are registered, when their utilization
increases significantly. This suggests that if Switzerland is to
obtain substantial additional reductions in premature cancer
mortality in the future (a decade or more from now) at a
modest cost, pharmaceutical innovation (registration of new
drugs) is needed today.
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Introduction
Previous authors have argued that ‘‘reducing premature
mortality is a crucial public health objective’’ [16]. A
widely used measure of premature mortality is years of
potential life lost (YPLL) before a given age (e.g., age 70),
i.e., the number of years not lived by an individual who
died before that age [1]. Statistics of YPLL are published
by the World Health Organization, the OECD, and gov-
ernment agencies of the U.S., Switzerland, and other
countries. Burnet et al. [2] argue that YPLL ‘‘should be
considered when allocating research funds’’.
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As shown in Fig. 1, in Switzerland in 2010, cancer
(malignant neoplasms) was the largest cause of premature
mortality: the number of years of potential life lost before
age 70 (YPLL70) due to cancer was 44 % larger than
YPLL70 due to external causes and 138 % larger than
YPLL70 due to diseases of the circulatory system. How-
ever, as shown in Fig. 2, the premature cancer mortality
rate has been declining; it declined about 27 % between
1995 and 2010. The cancer incidence rate remained
approximately constant during that period.
While the premature mortality rate from all cancers
combined has been declining in Switzerland, Fig. 3 indi-
cates that there has been considerable variation in the rate
of decline across cancer sites. During the period
1995–2012, premature (before age 75) mortality from
cancer of lymphoid, hematopoietic, and related tissue
declined 31 %, and from breast cancer declined 38 %, but
premature mortality from lip, oral cavity, and pharynx
cancer increased 14 %, and from cancer of endocrine
glands and related structures increased 19 %. This varia-
tion in the rate of decline of premature mortality cannot be
explained by variation in the rate of decline of incidence.
In this paper, I will analyze the effect that pharmaceu-
tical innovation has had on premature cancer mortality in
Switzerland during the period 1995–2012.1 As shown in
Fig. 4, the number of drugs used to treat cancer that had
ever been launched in Switzerland increased almost
fivefold between 1980 and 2010; the number of ‘‘cancer
drugs’’ (antineoplastic and immunomodulating agents)
used to treat cancer increased almost sixfold.
The analysis will be performed using fixed-effects and
long-differences research designs (see McKinnish [12]) based
on longitudinal disease-level data. In essence, I will investi-
gate whether the cancer sites that experienced more pharma-
ceutical innovation had larger declines in the premature
mortality rate, controlling for changes in the incidence rate.
Figure 5 illustrates that the rate of pharmaceutical innovation,
as measured by the number of drugs launched during the
period 1986–2011, varied considerably across cancer sites.
Twenty-nine drugs were launched for breast cancer, while
only 15 or 16 drugs were launched for each of three other types
of cancer: connective and soft tissue, male genital organs, and
female genital organs.
The analysis will be based on aggregate data—longitu-
dinal data on 13 cancer sites2—rather than patient-level
data. Stukel et al. [20] argue that comparisons of outcomes
between patients treated and untreated in observational
studies may be biased due to differences in patient prog-
nosis between groups, often because of unobserved treat-
ment selection biases. I believe that difference-in-
differences estimates based on aggregate panel data are
much less likely to be subject to unobserved treatment
selection biases than estimates based on cross-sectional
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Fig. 1 Premature (before age
70) mortality rates from three
largest causes, Switzerland 2010
1 Lichtenberg [10] analyzed the impact of pharmaceutical innovation
and other types of medical innovation on cancer mortality in the US
during the period 2000–2009. However, as the Commonwealth Fund
[3] demonstrated, the US Health Care System differs dramatically
from the health care systems of other OECD countries, including
Switzerland. For example, in 2008, per-capita spending on health was
63 % higher in the US than it was in Switzerland. In 2012, per-capita
expenditure on pharmaceuticals was 80 % higher in the US than it
was in Switzerland.
2 The 13 cancer sites are the malignant neoplasm ICD-10 blocks
defined by the World Health Organization [21].
3 Jalan and Ravallion [7] argued that ‘‘aggregation to village level
may well reduce measurement error or household-specific selection
bias’’ (p. 10).
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Fig. 2 Cancer incidence rate
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Fig. 3 Log change in years of
potential life lost before age 75,
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Fig. 4 Number of drugs used to
treat cancer ever launched in
Switzerland, 1980–2010
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analyze (premature mortality rates) are not subject to lead-
time bias.4
In ‘‘Premature cancer mortality model ‘‘, I describe an
econometric model of premature cancer mortality. The data
sources used to construct the data to estimate this model are
described in ‘‘Data’’. Empirical results are presented in
‘‘Empirical results’’. Key implications of the estimates are
discussed in ‘‘Discussion’’. ‘‘Summary and conclusions’’
provides a summary and conclusions.
Premature cancer mortality model
In his model of endogenous technological change, Romer
[17] hypothesized an aggregate production function such
that an economy’s output depends on the ‘‘stock of ideas’’
that have previously been developed, as well as on the
economy’s endowments of labor and capital. The prema-
ture mortality model that I will estimate may be considered
a health production function, in which premature mortality
is an inverse indicator of health output or outcomes, and
the cumulative number of drugs approved is analogous to
the stock of ideas. The first model will be of the following
form:
lnðYPLL75s;tÞ ¼ bkCUM NCEs;tk
þ clnðCASES LT75s;t1Þ
þ pAGE DIAGs;t1 þ as þ dt þ es;t
ð1Þ
where
YPLL75s,t = years of potential life lost before age 75 from
cancer at site s per 100,000 people below age
75 in year t (t = 1995, … , 2012)
CUM_NCEs,t–k =
P
d INDds REGISTEREDd,t-k = the number
of new chemical entities (drugs) to treat cancer
at site s that had been registered in Switzerland
by the end of year t - k
INDds = 1 if drug d is used to treat (indicated for)
cancer at site s
= 0 if drug d is not used to treat (indicated for)
cancer at site s
REGISTEREDd,t–k = 1 if drug d was registered in Switzerland by
the end of year t - k
= 0 if drug d was not registered in Switzerland
by the end of year t – k
CASES_LT75s,t-1 = the number of new cases of cancer at site s
diagnosed in people below age 75 per 100,000
people below age 75 in year t - 1
AGE_DIAGs,t-1 = the mean age at which people who were
diagnosed with cancer at site s in year t - 1
were diagnosed
as = a fixed effect for cancer at site s
dt = a fixed effect for year t
The most recent available incidence data are for the year 2011
Inclusion of year and cancer-site fixed-effects controls
for the overall decline in premature cancer mortality and
for stable between-disease differences in premature mor-
tality.5 A negative and significant estimate of bk in Eq. (1)
would signify that diseases for which there was more
pharmaceutical innovation had larger declines in premature
mortality. bk  CUM NCE:;2012k CUM NCE:;1995kð Þ,
where CUM_NCE.,t-k is the mean of CUM_NCEs,t-k, is
an estimate of the decline in Swiss premature cancer
mortality during the sample period (1995–2012) that can be
attributed to the introduction of new drugs. The functional
form of Eq. (1) has the property of diminishing marginal
productivity: the absolute reduction in premature mortality
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C60 C63 male genital organs C45 C49 connecve and so ssue
C50 C50 breast C51 C58 female genital organs
C30 C39 respiratory system and intrathoracic
organs
Fig. 5 Number of drugs that had been launched in Switzerland for
treating five types of cancer, 5-year intervals, 1986–2011
4 Survival time for cancer patients is usually measured from the day
the cancer is diagnosed until the day they die. Patients are often
diagnosed after they have signs and symptoms of cancer. If a
screening test leads to a diagnosis before a patient has any symptoms,
the patient’s survival time is increased because the date of diagnosis is
earlier. This increase in survival time makes it seem as though
screened patients are living longer when that may not be happening.
This is called lead-time bias. It could be that the only reason the
survival time appears to be longer is that the date of diagnosis is
earlier for the screened patients, but the screened patients may die at
the same time they would have without the screening test. See
(National Cancer Institute [13]). 5 The year fixed effects also control for population growth.
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As illustrated by Fig. 6, the data exhibit heteroskedas-
ticity: cancer sites with larger total premature mortality
during 1995–2012 had smaller (positive and negative)
annual percentage fluctuations in YPLL75. Equation (1)
will therefore be estimated by weighted least-squares,
weighting by the mean premature mortality rate during
1995–2012 ((Rt YPLL75s,t)/18). The standard errors of
Eq. (1) will be clustered within cancer sites.
Although one would expect an increase in true cancer
incidence to increase premature cancer mortality, cancer
incidence rates are subject to measurement error, so one
should not necessarily expect the coefficient on measured
cancer incidence (c) to be positive. Let I and I* represent
measured and true cancer incidence, respectively. Then
I = (I/I*) 9 I*, and log(I) = log(I/I*) ? log(I*). Mea-
sured cancer incidence can increase for two reasons: an
increase in true cancer incidence, or an increase in the ratio
of measured incidence to true incidence. The latter could
occur as a result of increasing quantity or quality of cancer
screening. More and better cancer screening could lead to
earlier diagnosis, which might reduce premature mortality.
Therefore the effect on premature mortality of increases in
I* and increases in (I/I*) may offset one another: the for-
mer is likely to increase premature mortality, but the latter
may reduce it. For this reason, although controlling (in an
unrestrictive manner) for measured incidence in the pre-
mature mortality model seems appropriate, we should not
be surprised if we don’t find a significant effect of mea-
sured incidence on premature mortality.
Equation (1) also includes mean age at time of diagnosis
(AGE_DIAG) as an explanatory variable. Like the number
of cases diagnosed, mean age at time of diagnosis could
change for two reasons. First, the true mean age of onset of
the disease could change; a reduction in the true mean age
of onset would be likely to increase premature mortality.
Second, the lag from time of onset to time of diagnosis
could change; a reduction in this lag, which would reduce
mean age at time of diagnosis, would be likely to reduce
premature mortality. Hence, the sign of the coefficient (p)
on AGE_DIAGs,t-1 in Eq. (1) is ambiguous, a priori.
Nevertheless, it seems desirable to control for mean age at
time of diagnosis in the premature mortality equation.6
The measure of pharmaceutical innovation in Eq. (1)—
the number of chemical substances previously commercial-
ized to treat a disease—is not the theoretically ideal mea-
sure. Premature mortality is presumably more strongly
related to the drugs actually used to treat a disease than it is
to the drugs that could be used to treat the disease. A
preferable measure is the mean vintage of drugs used to treat
cancer at site s in year t, defined as VINTAGEst ¼P
d QdstLAUNCH YEARd=
P
dQdst, where Qdst = the
quantity of drug d used to treat cancer at site s in year t, and
LAUNCH_YEARd = the world launch year of drug d.
7
Unfortunately, measurement of VINTAGEst is infeasible:
even though data on the total quantity of each drug in each
year (Qd.t = Rs Qdst) are available, many drugs are used to
treat multiple diseases,8 and there is no way to determine the
quantity of drug d used to treat cancer at site s in year t.9
However, Lichtenberg [9] showed that in France, there is a
highly significant positive correlation across drug classes
between changes in the (quantity-weighted) vintage of drugs
and changes in the number of chemical substances previ-
ously commercialized within the drug class.
Pharmaceutical innovation is not the only type of medical
innovation that is likely to reduce premature mortality. Other
medical innovation, such as innovation in diagnostic imag-
ing, surgical procedures, and medical devices, is also likely
to affect premature mortality. Therefore, measures of these
other types of medical innovation should be included in the
Eq. (1). Unfortunately, longitudinal disease-level measures
of non-pharmaceutical medical innovation are not available
for Switzerland. However, failure to control for non-phar-
maceutical medical innovation is unlikely to bias estimates
of the effect of pharmaceutical innovation on premature
mortality, for two reasons. First, more than half of US
funding for biomedical research came from pharmaceutical
and biotechnology firms [4]. Much of the rest came from the
6 Controlling for the distribution of people diagnosed by cancer stage
(local, regional, distant) might also be desirable, although due to the
phenomenon of ‘stage migration’ [5], measured changes in the stage
distribution may be due to improvements in diagnostic imaging—
metastases that had formerly been silent and unidentified are now
identified—rather than a true change in the disease distribution.
Consistent with that phenomenon, in an analysis of US data,
Lichtenberg (2014) found no relationship across cancer sites between
the change in the stage distribution and the change in the age-adjusted
mortality rate. Data on the number of people diagnosed by cancer site,
stage, and year are not available for Switzerland.
7 According to the Merriam Webster dictionary, one definition of
vintage is ‘‘a period of origin or manufacture (e.g., a piano of 1845
vintage)’’. http://www.merriam-webster.com/dictionary/vintage.
Solow [19] introduced the concept of vintage into economic analysis.
Solow’s basic idea was that technical progress is ‘‘built into’’
machines and other goods and that this must be taken into account
when making empirical measurements of their roles in production.
This was one of the contributions to the theory of economic growth
that the Royal Swedish Academy of Sciences cited when it awarded
Solow the 1987 Alfred Nobel Memorial Prize in Economic Sciences
[15].
8 For example, dactinomycin is used to treat C45–C49 connective
and soft tissue neoplasms, C51–C58 female genital organ neoplasms,
C60–C63 male genital organ neoplasms, and C64–C68 urinary organ
neoplasms.
9 Outpatient prescription drug claims usually don’t show the
indication of the drug prescribed. Claims for drugs administered by
doctors and nurses (e.g., chemotherapy) often show the indication of
the drug, but these account for just 15 % of drug expenditure. These
data are not available for Switzerland.
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federal government (i.e., the NIH), and new drugs often
build on upstream government research [18]. The National
Cancer Institute [14] says that it ‘‘has played an active role
in the development of drugs for cancer treatment for
50 years… [and] that approximately one half of the
chemotherapeutic drugs currently used by oncologists for
cancer treatment were discovered and/or developed’’ at the
National Cancer Institute.
Second, previous research based on US data indicates
that non-pharmaceutical medical innovation is not posi-
tively correlated across diseases with pharmaceutical
innovation. Lichtenberg [9] showed that, in the US during
the period 1997–2007, the rate of pharmaceutical innova-
tion was not positively correlated across diseases with the
rate of medical procedure innovation and may have been
negatively correlated with the rate of diagnostic imaging
innovation. Also, Lichtenberg [10] found that estimates of
the effect of pharmaceutical innovation on US cancer
mortality rates were insensitive to the inclusion or exclu-
sion of measures of non-pharmaceutical medical innova-
tion. This suggests that failure to control for other medical
innovation is unlikely to result in overestimation of the
effect of pharmaceutical innovation on longevity growth.
In Eq. (1), premature mortality from cancer at site s in
year t depends on the number of new chemical entities
(drugs) to treat cancer at site s launched in Switzerland by
the end of year t - k, i.e., there is a lag of k years. Eq. (1)
will be estimated for different values of k: k = 0, 5, 10, 15,
20, 25, 30.10 One would expect there to be a substantial lag
because new drugs diffuse gradually—they won’t be used
widely until years after commercialization. Figure 7 shows
data on the mean number of standard units11 of cancer
drugs sold (in thousands) in Switzerland in 2012, by period
of launch in Switzerland. Mean utilization in 2012 of drugs
launched after 2000 is only 19 % as high as mean uti-
lization of drugs launched during 1951–1990, and 11 % as
high as mean utilization of drugs launched during
1991–2000.
The effect of a drug’s launch on premature mortality is
likely to depend on both the quality and the quantity of the
drug. Indeed, it is likely to depend on the interaction
between quality and quantity: a quality improvement will
have a greater impact on mortality if drug utilization
(quantity) is high. Although newer drugs tend to be of
higher quality than older drugs (see [11]), the relative
quantity of very new drugs is quite low, so the impact on
mortality of very new drugs is lower than the impact of
older drugs.
Premature mortality in year t presumably depends more
on the number of drugs actually used to treat patients in
year t (N_NCE_TREATs,t) than it does on the number of
drugs registered by year t (or t - k). (Some drugs are not
used until several years after registration.) CUM_NCEs,t-k
might be considered a ‘‘noisy indicator’’ of
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Fig. 6 Plot of the residuals
from the (unweighted)
regression ln(YPLL75st) = as ?
dt ? est against total premature
(before age 75) mortality during
1995–2012 (Rt YPLL75st)
10 A separate model is estimated for each value of k, rather than
including multiple values (CUM_NCEi,t-1, CUM_NCEi,t-2,
CUM_NCEi,t-3,…) in a single model because CUM_NCE is highly
serially correlated (by construction), which would result in extremely
high multicollinearity if multiple values were included.).
11 The number of standard ‘dose’ units sold is determined by taking
the number of counting units sold divided by the standard unit factor
which is the smallest common dose of a product form as defined by
IMS HEALTH. For example, for oral solid forms the standard unit
factor is one tablet or capsule whereas for syrup forms the standard
unit factor is one teaspoon (5 ml) and injectable forms it is one
ampoule or vial. Other measures of quantity, such as the number of
patients using the drug, prescriptions for the drug, or defined daily
doses of the drug, are not available.
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subject to measurement error. Measurement error often
biases coefficients towards zero. McKinnish [12] argued
that when explanatory variables in panel data models are
subject to measurement error, long-difference estimates
may be less downward biased than fixed-effects esti-
mates,12 and that ‘‘it seems prudent for researchers to
estimate both fixed-effects and long-differences models
whenever feasible’’. Therefore, in addition to estimating
the fixed-effects model of the level of premature mortality
(Eq. 1) using annual data, I will estimate a long-difference
model that can be derived from Eq. (1). A special case of
Eq. (1), when t = 2012 (the final year of the sample per-
iod) and incidence and mean age at diagnosis are excluded
(for simplicity) is:
ln YPLL75s;2012
  ¼ bkCUM NCEs;2012k þ as þ d2012
þ es;2012
ð2Þ
When t = 1995 (the initial year of the sample period) and
incidence and mean age at diagnosis are excluded:
ln YPLL75s;1995
  ¼ bkCUM NCEs;1995k þ as þ d1995
þ es;1995
ð3Þ
Subtracting (3) from (2) yields a simple linear regression:
ln YPLL75s;2012
  ln YPLL75s;1995
 
¼ bk CUM NCEs;2012k  CUM NCEs;1995k
 
þ d2012  d1995ð Þ þ es;2012  es;1995
  ð4Þ
It is quite plausible that (CUM_NCEs,2012-k -
CUM_NCEs,1995-k) is subject to less measurement error
than CUM_NCEs,t-k: the long-run (12-years) change in the
number of drugs used to treat a condition can be measured
more reliably than the number of drugs used to treat a
condition in a particular year.
The measure of pharmaceutical innovation,
CUM_NCEs,t-k =
P
d INDds LAUNCHd,t-k, is based on
whether drug d had an indication for cancer at site s at the
end of 2011. One would prefer to base the measure on
whether drug d had an indication for cancer at site s at the
end of year t - k. FDA data indicate that about one in four
new molecular entities has supplemental indications, i.e.,
indications approved after the drug was initially launched.13
In Eq. (1), the measure of premature mortality is the
number of years of potential life lost before age 75. To
assess the robustness of my results, I will estimate models
similar to Eq. (1), using the age threshold 65 as well as 75.
Chemical substances are divided into different groups
according to the organ or system on which they act and
their therapeutic, pharmacological, and chemical proper-
ties. In the anatomical therapeutic chemical (ATC) clas-
sification system developed by the World Health
Organization Collaborating Centre for Drug Statistics
Methodology, drugs are classified in groups at five dif-
ferent levels. The highest (1st) level is the ‘‘anatomical
main group’’ level; there are 14 anatomical main groups.
The 2nd, 3rd, 4th, and 5th levels are ‘‘therapeutic sub-














1951 1990 (N = 1991)42 2000 (N = 1002)13 2011 (N = 31)
Fig. 7 Mean quantity (000s of
standard units) of cancer
molecules sold in Switzerland in
2012, by year of launch of
molecule in Switzerland
12 She provides (in her Table 4) an empirical example in which the
magnitude of the 7-year long-difference estimate is more than three
times the magnitude of the fixed-effects estimate. 13 Source: Drugs@FDA Data Files.
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subgroup’’, and ‘‘chemical substance’’, respectively.14
Premature mortality from a disease may depend on the
number of chemical (or pharmacological) subgroups that
have previously been developed to treat the disease rather
than, or in addition to, the number of chemical substances
(drugs) that have previously been developed to treat the
disease. This will be investigated by estimating versions
of Eq. (4) in which (CUM_SUBGROUPs,2012 - k -
CUM_SUBGROUPs,1995 - k) is included in addition to or






IND_SUBGROUPgs = 1 if any drugs in chemical subgroup g
are used to treat (indicated for) cancer
at site s
= 0 if no drugs in chemical subgroup g
are used to treat (indicated for) cancer
at site s
REGISTERED_SUBGROUPg,t-k = 1 if any drugs in chemical subgroup g
had been registered in Switzerland by
the end of year t - k
= 0 if no drugs in chemical subgroup g
had been registered in Switzerland by
the end of year t - k
Data
NCE registrations in Switzerland (registered)
Data on new chemical entities registered in Switzerland were
constructed from the expanded list of preparations of human
and veterinary medicines published by the Swiss Agency for
Therapeutic Products. This list includes WHO ATC codes
and Swiss registration dates of pharmaceutical preparations.
Drug indications (IND)
Data on drug indications were obtained from The´riaque, a
database of official, regulatory, and bibliographic information
on all drugs available in France,15 intended for health pro-
fessionals. This database is produced by the Centre National
Hospitalier d’Information sur le Me´dicament. In this database,
drugs are coded according to WHO ATC codes, and diseases
are coded according to WHO ICD-10 codes.16
Appendix Table 3 shows drugs (sorted by Swiss launch
year) used to treat various types of cancer in Switzerland.
Premature mortality data (YPLL75, YPLL65)
Data on years of potential life lost before ages 75 and 65,
by cancer site and year (1995–2012), were constructed
from data provided by the Federal Statistics Office.17
Cancer incidence data
Data on the number of new cancer cases, by cancer site,
age, and year, were obtained from the National Institute for
Cancer Epidemiology and Registration.18 This source also
enabled calculation of the mean age of people diagnosed
with cancer, by cancer site and year.
Appendix Table 4 shows data on the number of years of
potential life lost and the number of new cases diagnosed
(in the previous year) before ages 75 and 65, by cancer site,
in 1995 and 2012.
Empirical results
Estimates of CUM_NCE coefficients from fixed-effects
(FE) and long-difference (LD) models of premature cancer
mortality are presented in Table 1. All models controlled
for cancer incidence and mean age at diagnosis in the
previous year. Controlling for these variables had little
effect on estimates of the CUM_NCE coefficients; to
conserve space, coefficients on cancer incidence and mean
age at diagnosis are not shown in Table 1.
The estimates in the top part of the table (lines 1–3) are
of models in which the age threshold for measuring pre-
mature mortality is age 75. The estimates in the bottom part
14 For example, the five levels associated with the chemical subgroup
‘‘nitrogen mustard analogues’’ are:
L Antineoplastic and immunomodulating agents
L01 Antineoplastic agents
L01A Alkylating agents









15 A similar database is not available for Switzerland, but the
indications of drugs are unlikely to differ substantially across
countries.
16 Many drug databases contain information about drug indications,
but this information is usually in text form only.
17 Mortality data are reported in 5-years age groups. I assume that
deaths in a 5-year age group occur at the midpoint of the age group.
For example, I assume that deaths at age 35–39 years occurred at age
37.5. The Association of Public Health Epidemiologists in Ontario [1]
uses this method.
18 The National Institute for Cancer Epidemiology and Registration
was founded in May 2007 by the Swiss Cancer Registries Network
and Oncosuisse with the contribution of the University of Zurich.
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of the table (lines 4–6) are of models in which the age
threshold for measuring premature mortality is age 65. For
each age threshold, estimates based on three alternative
assumed lags (5, 10, and 15 years) between drug registra-
tion and premature mortality are presented.19
The left side of line 1 of Table 1 shows the FE model
estimate of the effect of cumulative NCEs registered on the
log of the premature (before age 75) cancer mortality rate
5 years later. The estimate is negative and significant
(p value = 0.05). It indicates that premature cancer mor-
tality was reduced by 1.2 % by an additional drug registered
at least 5 years earlier. The right side of line 1 shows that the
magnitude of the corresponding LD model estimate is 48 %
larger; this is consistent with the hypothesis that the long-run
(12-years) change in the number of drugs used to treat a
condition can be measured more reliably than the number of
drugs used to treat a condition in a particular year. This
estimate is just slightly less significant (p value = 0.06).
In line 2, the assumed lag between cumulative NCE
launches and premature mortality is 10 years. The FE
estimate of b10 is 36 % larger than the FE estimate of b5,
and the LD estimate of b10 is 73 % larger than the LD
estimate of b5. As discussed above, since mean utilization
of new drugs is much lower than mean utilization of older
drugs, a more recent drug registration may have a smaller
marginal effect on premature mortality than an earlier drug
registration even if the average quality of newer drugs is
higher. The LD estimate of b10 indicates that premature
cancer mortality was reduced by 3.1 % by an additional
drug registered at least 10 years earlier.
In line 3, the assumed lag between cumulative NCE
launches and premature mortality is 15 years. The FE
estimate of b15 is 33 % larger than the FE estimate of b10:
the LD estimate of b15 is approximately equal to the LD
estimate of b10. Both estimates are highly significant
(p value\0.01). Figure 8 depicts the correlation across 13
cancer sites between the 1995–2012 log change in the
premature (before age 75) mortality rate and the number of
NCEs registered during 1980–1997 (i.e., the increase in
cumulative NCEs registered until 15 years before).20 The
number of NCEs registered during 1980–1997 explains
63 % of the variation across cancer sites in the 1995–2012
log change in the premature (before age 75) mortality rate.
As shown in lines 4–6 of Table 1, the estimates of
models in which the age threshold for measuring premature
mortality is age 65 are qualitatively similar to the estimates
of models in which the age threshold for measuring pre-
mature mortality is age 75.
Overall, the estimates in Table 1 indicate that premature
cancer mortality before ages 75 and 65 is significantly
inversely related to the cumulative number of NCEs regis-
tered 5, 10, and 15 years earlier (controlling for the number
of people diagnosed and mean age at diagnosis); that LD
estimates of the effect of NCE registrations are considerably
larger than FE estimates (consistent with the presence of
measurement error in the regressor); and that the marginal
effect of more recently registered (and less frequently used)
NCEs is smaller than the marginal effect of older NCEs.
As discussed earlier, premature mortality from a disease
may depend on the number of chemical (or pharmacolog-
ical) subgroups that have previously been developed to
treat the disease rather than, or in addition to, the number
of chemical substances (drugs) that have previously been
developed to treat the disease. I investigated this possibility
by estimating LD models with a 15-years lag in which
(CUM_SUBGROUPs,1997 - CUM_SUBGROUPs,1980) was
included in addition to (CUM_NCEs,1997 -
CUM_NCEs,1980). In models of both premature mortality
before age 75 and premature mortality before age 65, only
the coefficients on (CUM_NCEs,1997 - CUM_NCEs,1980)
were significant. That finding suggests that drugs (chemical
substances) within the same class (chemical subgroup) are
not ‘‘therapeutically equivalent’’,21 i.e., they do not have
essentially the same effect in the treatment of a disease or
condition.
Discussion
Now I will use the estimates presented in Table 1 to cal-
culate the number of life-years gained in 2012 from phar-
maceutical innovation and drug expenditure per life-year
gained. These calculations are shown in Table 2. Line 1
shows the premature (before ages 75 and 65) mortality
rates of all cancers combined in 2012. The estimates imply
that, in the absence of previous pharmaceutical innovation,
these premature mortality rates would have been higher
than they actually were. On the other hand, 2012 phar-
maceutical expenditure would have been lower in the
absence of previous pharmaceutical innovation. I will
19 Estimates of coefficients based on zero lag between drug
registration and premature mortality (k = 0) were never statistically
significant. This is not surprising, since as discussed above new drugs
diffuse gradually—they aren’t used widely until years after
commercialization.
20 Figure 8 depicts a simple correlation; controlling for the long-run
change in the incidence rate and mean age at diagnosis has virtually
no effect on this correlation. Neither of those variables is significant
in any of the LD models.
21 According to one medical dictionary, drugs that have ‘‘essentially
the same effect in the treatment of a disease or condition’’ are
therapeutically equivalent. Drugs that are therapeutically equivalent
may or may not be chemically equivalent, bioequivalent, or
generically equivalent. http://medical-dictionary.thefreedictionary.
com/therapeutic?equivalent.
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calculate 12 (=2 9 3 9 2) different estimates of life-years
gained and their average cost, based on 2 estimation
methods (FE and LD), 3 lags (5, 10, and 15 years), and 2
age thresholds (75 and 65).
As shown in line 4, the mean 1997–2012 increase in the
cumulative number of drugs registered 5, 10, and 15 years
earlier was 9.2, 11.8, and 11.3, respectively. As shown in
line 6, the log change in premature mortality due to the
increase in the cumulative number of drugs registered is bk
9 DCUM_NCEk. For example, the LD estimate of b5 9
DCUM_NCE5 (=-0.164) implies that the 2012 mortality
rate before age 75 would have been 18 % (=exp(0.164) - 1)
higher if DCUM_NCE5 had been equal to zero: the mortality
rate would have been 1513 rather than its actual value of
1284. As shown in line 7, that implies that 17,092 [=(1513 -
1284) 9 7.5] life-years before age 75 were gained in 2012
due to pharmaceutical innovation during 1990–2007. The
LD estimates of the number of life-years before age 75
Table 1 Estimates of CUM_NCE coefficients from fixed-effects and long-difference models of premature cancer mortality
Line Parameter Fixed-effects model (Eq. 1); n = 234 Long-difference model (Eq. 4); n = 13
Estimate Standard error Z Pr[ |Z| Estimate Standard error t value Pr[ |t|
A. Dependent variable = ln(YPLL75s,t); weight = ((Rt YPLL75s,t)/18)
1 b5 -0.012 0.006 -1.98 0.048 -0.018 0.008 -2.14 0.061
2 b10 -0.017 0.004 -3.95 \0.0001 -0.031 0.010 -3.01 0.015
3 b15 -0.022 0.005 -4.46 \0.0001 -0.029 0.007 -4.02 0.003
B. Dependent variable = ln(YPLL65s,t); weight = ((Rt YPLL65s,t)/18)
4 b5 -0.015 0.007 -2.05 0.040 -0.020 0.009 -2.25 0.051
5 b10 -0.019 0.005 -3.44 0.001 -0.033 0.012 -2.85 0.019
6 b15 -0.025 0.006 -3.99 \0.0001 -0.036 0.007 -5.02 0.001
C00 C14 lip, oral cavity and pharynx
C15 C26 digesve organs
C30 C39 respiratory system and
intrathoracic organs
C40 C41 bone and arcular carlage
C43 C44 skin
C45 C49 connecve and so ssue
C50 breast
C51 C58 female genital organs
C60 C63 male genital organs
C64 C68 urinary organs
C69 C72 eye, brain and central nervous
system
C73 C75 endocrine glands and related
structures






































Number of drugs launched, 1980 1997
Note: bubble size is proporonal to total amount of premature (before age 75) mortality during 1995 2012.
Fig. 8 Relationship across cancer sites between number of drugs launched, 1980–1997, and log change in premature mortality, 1995–2012
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gained from pharmaceutical innovation during 1985–2002
and 1980–1997 are more than twice as great.22
Line 8 of Table 2 shows estimates of expenditure in
2012 on drugs used to treat cancer that were registered
during the period 1995 - k to 2012 - k (k = 5, 10, 15).
Data from IMS Health were used to estimate 2012
expenditure on each of the molecules listed in Appendix
Table 3.23 Our figures are likely to overstate expenditure
on drugs used to treat cancer, for two reasons. First, some
of these molecules [especially those not in anatomical main
group L (antineoplastic and immunomodulating agents)]
are used to treat diseases other than cancer. Second, the
IMS data do not account for any rebates paid by drug
manufacturers to payers, although according to
pharmaceutical industry executives rebates play a much
smaller role in Switzerland than they do in some other
countries (e.g., the USA).
The IMS Health data indicate expenditure by or on
behalf of patients of all ages. Data from the National
Institute for Cancer Epidemiology and Registration indi-
cate that 70 % of patients diagnosed with cancer are
diagnosed before the age of 75, and 41 % are diagnosed
before the age of 65. I assumed that 70 % of 2012
expenditure on drugs used to treat cancer was for patients
below age 75 and that 41 % of 2012 expenditure on drugs
used to treat cancer was for patients below age 65. Since
patients diagnosed before age 75 (for example) may con-
tinue to incur drug expenditure after age 75, these
assumptions are also likely to be conservative, i.e., to
overstate expenditure on drugs used to treat cancer on
patients below age 75.
Line 9 of Table 2 shows estimates of the cost per life-
year gained from previous pharmaceutical innovation. The
FE estimates of the cost per life-year gained before ages 75
and 65 in 2012 from drugs launched during 1990–2007 are
$32,287 and $40,010, respectively. However, as McKin-
nish [12] observed, ‘‘if the independent variable is an
imprecise measure of the relevant factor, coefficient esti-
mates from [FE] models can be severely attenuated
towards zero’’. Hence, the FE estimates may well under-
state the number of life-years gained, and we may also be
overestimating the cost. The LD estimates of the cost per
life-year gained before ages 75 and 65 in 2012 from drugs
launched during 1990–2007, which are likely to be less
Table 2 Calculation of number of life-years gained in 2012 from pharmaceutical innovation and of drug expenditure per life-year gained
Line Before age 75 Before age 65
1 2012 premature cancer mortality rate per 100,000
population (RATE)
1284 540
2 2012 population (POP) 7,471,495 6,724,518
3 Lag (number of years) from drug registration to
premature mortality (k)
5 10 15 5 10 15
4 Mean 1997–2012 increase in cumulative number of drugs
registered k years earlier (DCUM_NCEk)
9.2 11.8 11.3 9.2 11.8 11.3
5 bk (from Table 1) FE est. -0.012 -0.017 -0.022 -0.015 -0.019 -0.025
LD est. -0.018 -0.031 -0.029 -0.020 -0.033 -0.036
6 bk 9 DCUM_NCE FE est. -0.111 -0.195 -0.249 -0.135 -0.222 -0.286
LD est. -0.164 -0.368 -0.330 -0.184 -0.390 -0.404
7 Reduction in life-years lost due to pharmaceutical
innovation: GAIN = [exp(-bk 9 DCUM_NCEk) - 1]
9 RATE 9 (POP/100,000)
FE est. 11,238 20,711 27,099 5,273 9,012 12,037
LD est. 17,092 42,688 37,535 7,357 17,327 18,117
8 Estimated expenditure (in thousands) in 2012 on drugs
used to treat cancer registered during the period
1995-k to 2012-k (COST)
$362,831 $226,185 $120,804 $210,960 $131,510 $70,239
9 Cost per life-year gained (=COST/GAIN) FE est. $32,287 $10,921 $4,458 $40,010 $14,593 $5,835
LD est. $21,228 $5,299 $3,218 $28,673 $7,590 $3,877
22 Although the percentage reductions in premature mortality due to
pharmaceutical innovation are slightly larger before age 65 than they
are before age 75, the (absolute) reduction in life-years lost before age
65 is considerably smaller, primarily due to the lower mortality rate
(540 vs. 1284) and also to the smaller population.
23 2012 expenditure on the molecules listed in Appendix Table 3, by
period of registration, are as follows:
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attenuated towards zero, are at least 28 % lower: $21,228
and $28,673, respectively. Moreover, the LD estimates
indicate that the cost per life-year before age 75 gained
from drugs launched during 1985–2002 and 1980–1997
were considerably lower: $5299 and $3218, respectively.24
Hirth et al. [6] performed a search of the value-of-life
literature and identified 41 estimates of the value of life
from 37 articles.25 From estimates of the value of life, they
calculated estimates of the value (in 1997 dollars) of a
quality-adjusted life-year (QALY).26 Four types of meth-
ods were used to produce those estimates: revealed pref-
erence/job risk, contingent valuation, revealed preference/
non-occupational safety, and human capital. Median
implied values (in 1997 and 2012 dollars27) of a QALY
estimated in those studies are shown in the following table.
Study method Number of
studies






Revealed preference/job risk 19 $428,286 $612,449




Human capital 6 $24,777 $35,431
The LD estimates in line 9 of Table 2 of the cost per
life-year gained before ages 75 and 65 in 2012 from drugs
launched during 1990–2007 ($21,228 and $28,673,
respectively) are lower than the median value in 2012
dollars of a QALY obtained from human capital studies
($35,431). Moreover, the median value of a QALY implied
by other study methods was 3.8–17.3 times as high as the
median value implied by human capital studies.
Summary and conclusions
The premature cancer mortality rate has been declining in
Switzerland, but there has been considerable variation in
the rate of decline across cancer sites. I analyzed the effect
that pharmaceutical innovation has had on premature
cancer mortality in Switzerland during the period
1995–2012, by investigating whether the cancer sites that
experienced more pharmaceutical innovation had larger
declines in premature mortality, controlling for the number
of people diagnosed and mean age at diagnosis.
Premature cancer mortality before ages 75 and 65 is
significantly inversely related to the cumulative number of
NCEs registered 5, 10, and 15 years earlier. The number of
NCEs registered during 1980–1997 explains 63 % of the
variation across cancer sites in the 1995–2012 log change
in the premature (before age 75) mortality rate.
Controlling for the cumulative number of drugs, the cumu-
lative number of chemical subgroups does not have a statisti-
cally significant effect on premature mortality. This suggests
that drugs (chemical substances) within the same class
(chemical subgroup) are not ‘‘therapeutically equivalent’’.
Over 17,000 life-years before age 75 were gained in 2012
due to drugs registered during 1990–2007. The number of
life-years before age 75 gained from drugs registered during
two earlier periods (1985–2002 and 1980–1997) were more
than twice as great. Since mean utilization of new drugs is
much lower than mean utilization of older drugs, more
recent drug registrations may have a smaller effect on pre-
mature mortality than earlier drug registrations even if the
average quality of newer drugs is higher.
Estimates of the cost per life-year gained before ages 75
and 65 in 2012 from drugs launched during 1990–2007 are
$21,228 and $28,673, respectively. These figures are below
even the lowest estimates from the value-of-life literature
of the value of a QALY. The estimates indicate that the
cost per life-year before age 75 gained from drugs launched
during earlier periods (1985–2002 and 1980–1997) were
considerably lower: $5299 and $3218, respectively.
The largest reductions in premature mortality occur at
least a decade after drugs are registered, when their uti-
lization increases significantly. This suggests that if
Switzerland is to obtain substantial additional reductions in
premature cancer mortality in the future (a decade or more
from now) at a modest cost, pharmaceutical innovation
(registration of new drugs) is needed today.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
Appendix
See Tables 3 and 4.
24 The cost per life-year before age 65 gained from drugs launched
during 1985–2002 and 1980–1997 were $7590 and $3877,
respectively.
25 Twenty-eight of the reviewed articles used US data; the remaining
articles used data from the UK (4), Canada (3), France (1), and
Denmark (1). National origin did not significantly affect the values.
26 Lichtenberg [8] demonstrated that, although the health of cancer
patients is less than perfect, the number of QALYs gained from
pharmaceutical innovation could be either greater than or less than the
number of life-years gained.
27 The US Consumer Price Index increased by 43 % between 1997
and 2012.
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